Roche today announced that it has signed a definitive Asset Purchase Agreement with AvanSci Bio for all products associated with high performance microdissection of tissue sections mounted on slides. The system consists of instrumentation, software and consumables used by researchers and clinicians to retrieve specific areas of tissue with high precision and purity for subsequent molecular analysis, including real-time PCR, microarrays and sequencing.
The technology AvanSci Bio, patent pending, includes MilliSect ™ automated equipment *. This unique technology is highly accurate, easy to use, and very accessible when compared with manual methods of dissection, and laser microdissection systems. The high specificity and quality MilliSect ™ system allows to obtain an enrichment of 90% of the tumor sample for molecular analysis. In 2015 will start up the beta testing of the system as part of a broader program of development of a future generation of equipment.
“This innovative system will expand our set of diagnostic methods that allow us to By connecting the diagnosis hematoxylin and eosin (H & amp; E) with the sequence analysis by preparing samples of high quality, “Dan Zabrowski, responsible for diagnostic unit for Textiles and Sequencing of Roche. “It will also enable us to face the critical challenge of tumor heterogeneity.”
The staining of tumor tissue provides researchers and clinicians important information on both the tissue context and their spatial relations, as the heterogeneity tumor (which follows the evolution of various subclones within the tumor). The information obtained from the marked areas allows researchers and clinicians to identify and extract with higher accuracy, regions of interest within the tissue, resulting in purer samples in sufficient quantity, which can then be used for sequencing. In addition, the analytical sensitivity of sequencing improves with greater purity of the sample and the subsequent data analysis and interpretation.
“We are delighted that Roche has decided to pursue this Asset Purchase Agreement of AvanSci Bio, “said Rob Perry, CEO of Bio AvanSci. “We see Roche as a leader in tissue diagnostics, molecular diagnostics and oncology, as well as in tumor samples enrichment technology, which puts them in a unique position to maximize the impact that our technology will have in the rapidly evolving field of sequencing and improve patient care. “
Roche continues to invest in bridge between pathology anatomy laboratories and genomics laboratories, as researchers and physicians increasingly rely on mounted tissue samples blades enriched with tumor cells sensitive and efficient for molecular analysis. As the tumor heterogeneity challenge is solved by means of diagnostic technologies based on tissues mounted on slides and improving the analytical sensitivity of next generation sequencing, patients can benefit more precise and effective targeted therapies.
* The MilliSect ™ device has a resolution level of 100mm2 100 μm2 (what is referred to as the AvanSci range of “meso” dissection).
Source: press release
No comments:
Post a Comment